Showing 5051-5060 of 8855 results for "".
- Isdin Taps Professional Golfer Jessica Korda As New Sports Ambassadorhttps://practicaldermatology.com/news/isdin-taps-professional-golfer-jessica-korda-as-new-sports-ambassador-1/2460330/Professional golfer and LPGA star Jessica Korda is ISDIN’s new sports ambassador. As part of the campaign, Korda is sharing how she keeps her skin looking its best on and off the golf course with ISDIN products. "ISDIN formulates unique and innovative products with
- BiomX’s BX001 for Acne-Prone Skin Performs Well in Phase 1 Trialhttps://practicaldermatology.com/news/biomxs-bx001-for-acne-prone-skin-performs-well-in-phase-1-1/2460328/BiomX Inc.’s lead candidate BX001 for acne-prone skin met its primary endpoint of safety and tolerability for both doses of BX001 as well as a statistically significant reduction of Cutibacterium acnes (C. acnes) levels for the high dos
- FDA Approves Lilly's Taltz for Treatment Of Pediatric Patients with Psoriasishttps://practicaldermatology.com/news/fda-approves-lillys-taltz-for-treatment-of-pediatric-patients-with-psoriasis/2460327/The FDA has approved a supplemental Biologics License Application (sBLA) for Eli Lilly and Company's Taltz (ixekizumab) injection, 80 mg/mL for the treatment of pediatric patients (ages 6 to under 18) with moderate to severe plaque psoriasis who are c
- Industry Responds to COVID-19: Allergan Foundation; AG Hair; Revancehttps://practicaldermatology.com/news/industry-responds-to-covid-19-allergan-foundation-ag-hair-revance/2460326/Allergan. Of the approximately $13 million in charitable grants the Allergan Foundation has awarded in 2020, a total of $2 million will be dedicated to more than 70 organizations responding to the local impact of the COVID-19 pandemic. Other grant recipients i
- Evolve BioSystems and Janssen to Study the Impact of B. infantis EVC001 for AD Prevention in Infantshttps://practicaldermatology.com/news/evolve-biosystems-and-janssen-to-study-the-impact-of-b-infantis-evc001-for-ad-prevention-in-infants/2460324/Evolve BioSystems, Inc. and Janssen Research & Development, LLC, are partnering to conduct a study looking at the potential role of B. infantis EVC001 in preventing early childhood atopic dermatitis (AD). The study will assess the effects of introducing a specific gut
- New AAAHC COVID-19 Guidelines Call for Postponing Elective or Non-Essential Visits and Surgerieshttps://practicaldermatology.com/news/new-aaahc-covid-19-guidelines-call-for-postponing-elective-or-non-essential-visits-and-surgeries/2460323/The Accreditation Association for Ambulatory Health Care (AAAHC) is calling for the postponement of elective or non-essential visits or surgeries in their newly released guidelines. For patients that require an office visit, increas
- Positive Phase 3 Results Reported for Medimetriks and Otsuka's AD Drughttps://practicaldermatology.com/news/positive-phase-3-results-reported-for-medimetriks-and-otsukas-ad-drug-1/2460322/Medimetriks Pharmaceuticals, Inc. and Otsuka Pharmaceuticals Co. Ltd.’s MM36 (difamilast) performed well in two Phase 3 Japanese clinical trials in adult and pediatric atopic dermatitis (AD) patients. Difamilast is a novel topical, non-steroidal phosphodiesterase IV (PDE4) inhibit
- FDA Greenlights Pfizer’s Eucrisa for Children As Young As Three Months With ADhttps://practicaldermatology.com/news/fda-greenlights-pfizers-eucrisa-for-children-as-young-as-three-months-with-ad/2460321/The U.S. Food and Drug Administration (FDA) gave its nod to Pfizer’s Eucrisa ointment, 2%, for children as young as age 3 months with mild-to-moderate atopic dermatitis (AD). Eucrisa was previously approved for use in adults and children 2 years of age and older. It is the first a
- COVID-19 Update: AAD, Others React to Potential Shortage of Malaria and Arthritis Drugshttps://practicaldermatology.com/news/covid-19-update-aad-others-react-to-potential-shortage-of-malaria-and-arthritis-drugs-1/2460320/The American Academy of Dermatology along with the Lupus Foundation of America, the American College of Rheumatology, and the Arthritis Foundation are concerned about hydroxychloroquine and chloroquine shortages and how it will impact patients with autoimmune diseases. The groups sent a
- 30% of Americans’ Jobs Negatively Impacted by COVID-19, Economic Fallouthttps://practicaldermatology.com/news/30-of-americans-jobs-negatively-impacted-by-covid-19-economic-fallout/2460317/While 35 percent of 1,000 Americans surveyed by LendEDU say that that their jobs have not been impacted by the Coronavirus, six percent report losing their job, 13 percent report that hours have been partially cut, and 11 percent have had hours cut entirely, though they still have their jobs.